NASDAQ : ABVX
Abivax S.A. (ABVX)Healthcare : Biotechnology$105,04
-1.95 (-1.82%) today
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Open
$106,84
High
$106,84
Low
$103,90
Mkt. cap
7.71B
Avg. vol.
1.75M
Volume
870.89K
52-wk high
$148,83
52-wk low
$69,81
Shares outstanding
73.43M
zacks.com - 18 Sep 2026 13:35
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers...
benzinga.com - 14 Sep 2026 04:55
ABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the...
zacks.com - 08 Sep 2026 13:00
Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings pr...
defenseworld.net - 27 Aug 2026 02:16
Shares of Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) have received an averag...
seekingalpha.com - 16 Jul 2026 10:25
Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obe...
zacks.com - 10 Jul 2026 10:56
After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good ...
cnbc.com - 10 Jul 2026 06:10
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel...
fool.com - 07 Jul 2026 19:15
The sky is the limit for these companies.
marketbeat.com - 07 Jul 2026 12:25
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the ...
globenewswire.com - 06 Jul 2026 16:05
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:0...
Latest reported earnings
Q1 2026
Report date: May 22, 2026
EPS / Est.
$-0.71 / $-1.07
+33.64% beat
Revenue / Est.
$1.51M / $401.13K
+277.30% beat
Past earnings
| Fiscal period | Report date | EPS / Est. | Revenue / Est. |
|---|---|---|---|
| Q4 2025 | Mar 23, 2026 | $-1.19 / $-1.7 (+30.00% beat) | $515.06K / $1.80M (-71.43% miss) |
| Q3 2025 | Dec 15, 2025 | $-2.472 / $-0.786 (-214.27% miss) | $2.40M / $1.35M (+78.51% beat) |
| Q2 2025 | Sep 8, 2025 | $-0.86 / $-0.9 (+4.44% beat) | $1.33M / $1.39M (-4.13% miss) |
| Q1 2025 | Jun 2, 2025 | $-0.969 / $-0.756 (-28.31% miss) | $1.16M / $3.35M (-65.30% miss) |
| Q4 2024 | Mar 24, 2025 | $-1.68 / $-1.588 (-5.79% miss) | $6.37M / $2.83M (+124.98% beat) |
| Q3 2024 | Nov 14, 2024 | $-0.699 / $-0.701 (+0.29% beat) | - / $3.59M (n/a) |
| Q2 2024 | Sep 9, 2024 | $-1.44 / $-0.74 (-94.59% miss) | $7.16M / $3.78M (+89.31% beat) |
| Q1 2024 | Apr 2, 2024 | $-1.939 / $-0.912 (-112.73% miss) | $2.50M / $2.47M (+1.27% beat) |
| Q2 2023 | Sep 21, 2023 | $-1.55 / $-0.671 (-130.99% miss) | $2.46M / $1.22M (+101.94% beat) |
| Q3 2022 | Dec 31, 2022 | $-1.946 / $-1.931 (-0.81% miss) | $2.42M / - (n/a) |
| Q2 2022 | Sep 15, 2022 | $-1.841 / - (n/a) | $2.33M / - (n/a) |
| Q4 2021 | Mar 16, 2022 | $-1.678 / - (n/a) | - / - (n/a) |
Marc de Garidel - CEO
Didier Blondel - EVice President, Chief Financial Officer & Board Secretary
James Berger - Global Head of Marketing
Patrick Malloy - Senior VP & Head of Investor Relations
Chris Rabbat - Vice President & Global Head of Medical Affairs
Hema Keshava - Senior Vice President of Finance
Kevin Shan - Vice President & Global Head of Biometrics
Mary Mantock - Senior VP & Global Head of Regulatory Affairs
Jerome Denis - Executive Vice President of Process Development & Manufacturing
Marc de Garidel - Chief Executive Officer & Director
Pierre Courteille - Chief Business Officer
Ida Hatoum - Chief People & Compliance Officer